

Cumulative Index 1991

Volume 7

<i>January</i>	ENDOCRINE CRISES, pages 1-256
<i>April</i>	DISASTER MANAGEMENT, pages 257-488
<i>July</i>	TOXIC EFFECTS OF DRUGS USED IN THE ICU, pages 489-762
<i>October</i>	OBSTETRIC EMERGENCIES, pages 763-946

Note: Page numbers of issue and article titles are in **boldface** type.

- Abdominal trauma, algorithm for, 385, 394-399
 complications, 386
 diagnostic procedures, monitoring, and treatment, 387
 in pregnancy, and abruptio placentae, 867
 Abruptio placentae, 865-875
 abdominal trauma and, 867
 age and, 867
 causes, 865-868
 coagulopathy in, 872-873
 cocaine abuse and, 868
 complications, 872
 delivery in, 871
 diagnosis, 868-869
 fetal effects, 873-874
 hypertension and, case study, 866-868
 intrauterine growth retardation following, 874
 management, 869-870
 multiparity and, 867
 pregnancy-induced hypertension and, 844-845
 uterine decompression and, 867-868
 Acetazolamide, hypophosphatemia due to, 204
 Acid-base balance, effect on internal potassium balance, 157, 159-160, 164
 fetal, obstetric conditions associated with, 924-925
 Acquired immunodeficiency syndrome (AIDS), adrenal insufficiency in, 29-30
 Addison's disease, 162
 Adenosine, for tachycardia in the intensive care unit, 508
 Adrenal cortex, zones of, 25
 Adrenal crisis, 23-42
 case study, 23-24
 diagnostic testing, 34-36
 treatment, 39
 complications, 39-40
 Adrenal gland, function of, normal, 25
 Adrenal medulla, description, 25
 α -Adrenergic blockers, for pheochromocytomas, 12-13
 β -Adrenergic blockers, for pheochromocytomas, 13
 for thyrotoxicosis, 65
 Adrenergic receptors, effect on cell function, 584-586
 Adrenocortical failure, clinical manifestations, 31-34
 Adrenocortical insufficiency, 24-25, 28-31
 in AIDS, 29-30
 primary, 28-30, 162
 secondary, 30-31
 Age, in abruptio placentae, 867
 in ectopic pregnancy, 901-902
 in shoulder dystocia, 853
 Agricultural poisonings, patient care following, 303
 AHPrBP, for severe hypercalcemia, 182-183
 AIDS. *See* *Acquired immunodeficiency syndrome*.

- Air Transportable Hospital, 261-262
- Airway management, in disaster victims, 327, 367-372
- following penetrating injuries, 407-409
- Albumin, in the intensive care unit, toxic effects, 714-716
- Albuterol, for acute bronchospasm, 641
- Alcoholism, hypophosphatemia due to, 204-206
- Aldosterone, effect on internal potassium balance, 157, 159
- physiology and regulation of, 27-28
- Algorithm, clinical, for fluid resuscitation in disasters, 363-381
- description, 366, 367-368, 371-372
 - effectiveness, 368-371
 - for truncal injury, 383-399
 - evaluation, 390, 391
 - methods, 384-387
 - results, 388-390
- Alkalosis, causes, 672
- metabolic, chloride for, 670-671
 - respiratory, as cause of hypophosphatemia, 205
 - hypophosphatemia due to, 204
- Alteplase, indications, 544
- mechanism of action, 544
- Amiodarone, for arrhythmias in the intensive care unit, 508
- and gastrointestinal upset, 513
 - hematologic effects, 514
 - immunologic effects, 514
 - neurologic toxicity caused by, 513
 - pulmonary toxicity induced by, 512
 - and thyroid abnormalities, 513-514
- Amniotic fluid, embolism. *See Embolism, amniotic fluid.*
- Amrinone, adverse effects, 601-602
- drug interactions with, 602
 - monitoring, 602
 - in newborns, 600
 - pharmacology, 599-600
 - structure of, 600
- Anemia, aplastic, angiotensin converting enzyme inhibitors and, 572
- anticonvulsants and, 528
- Anesthesia, for disaster victims, 339-361
- in earthquakes, in Armenia, 356-358
 - equipment, 343-350
 - anesthesia machines, 346-348
 - blood bank and laboratory equipment, 349-350
 - monitoring, 344-346
 - oxygen supply, 348-349 - induction, 351-352
 - maintenance, 352-355
 - preinduction, 350-351
 - in rail disasters, in Chechnabinsk, 359
 - strategies, 350
 - techniques, 350-355
 - training, 342-343
- general, in the intensive care unit, uses, 502
- halogenated, effects of epinephrine on, 591
- inhalational, for disaster victims, 346-348, 354
- in pregnancy-induced hypertension, 836
- regional, for disaster victims, 354-355
- Angioedema, angiotensin converting enzyme inhibitors and, 570
- Angiotensin converting enzyme (ACE)
- inhibitors, dosing, 573
 - toxic effects, 565-573
- angioedema, 570
 - cardiovascular, 566
 - dermatologic, 571
 - hematologic, 571-572
 - metabolic, 572
 - renal, 568-570
 - respiratory, 567-568
 - taste disturbances, 572-573
- Anistreplase, indications, 544
- mechanism of action, 544
- Antiarrhythmic agents, in the intensive care unit, 507-520
- changes in protein binding with, 510
 - congestive heart failure and, 510
 - drug interactions, 514-517
 - endocrine effects, 513-514
 - gastrointestinal effects, 513
 - hematologic effects, 514
 - hepatic dysfunction and, 509-510
 - immunologic effects, 514
 - indications, 507-508
 - neurologic toxicity caused by, 512-513
 - noncardiovascular toxicity, 511-514
 - pause-dependent torsades de pointes and, 511
 - pharmacokinetics and pharmacodynamics, changes in, 508-510
 - proarrhythmic effects, 510-511
 - pulmonary toxicity induced by, 512
 - renal failure and, 509
- Antibiotics, effect on nondepolarizing agents, 497
- Anticholinergic agents, administration and dosing, 643
- monitoring, 649
 - toxic effects, 643-644
- Anticoagulants, in the intensive care unit, 533-543
- oral, in pregnancy, 819-820
 - in pregnancy, in artificial heart valve patients, 792-793
 - heparin, 816-819
 - prophylactic, 822-823, 824
 - therapeutic, 821-822
- Anticonvulsant agents, in the intensive care unit, cardiac disease and, 522-523

- CNS effects, 528-529
 dose-related adverse reactions, 528-529
 dose-related hematologic side effects, 529
 gastrointestinal disease and, 523
 hepatic dysfunction and, 522
 idiosyncratic effects, 526-528
 inappropriate ADH secretion following, 529
 metabolic disease and, 523
 renal disease and, 522
 respiratory disease and, 523
 route of administration, complications, 529-530
 toxic effects, 521-532
 for seizures, toxic effects, 523-524
 for status epilepticus, toxic effects, 524-526
- Antidepressants, tricyclic, effects of epinephrine on, 591
- Antidiuretic hormone (ADH), secretion of, anatomy and physiology, 110
 control of, 110-112
- Antihistamines, side effects, in the intensive care unit, 500
- Antihypertensives, in pregnancy-induced hypertension, 835-836
- Antithrombin III deficiency, in pregnancy, 823
- Antithyroid drugs, for thyrotoxicosis, 63-64
- Aorta, coarctation of, pregnancy and, 783
- Aortic valve, stenosis of, pregnancy and, 787-788
- Armenia, earthquake in, anesthesia management in, 356-358
- Arrhythmia, digitalis toxicity and, 604
 epinephrine effects on, 588-589
 hypokalemia and, 148-149
 pregnancy and, 793
 treatment, in the intensive care unit, 507-520
- Arteriography, pulmonary, in pulmonary thromboembolism, in pregnancy, 816
- Asphyxia, fetal, intrauterine, 920
- Asphyxiants, inhalation of, 302
- Aspirin, for heparin-induced bleeding, 536
- Atrial septal defect, pregnancy and, 780
- Atropine, CNS effects, 643
 in digitalis toxicity, 606
 monitoring, 649
 for peripheral muscarinic syndrome, 314
- Barbiturates, side effects, in the intensive care unit, 500-501
- Benzodiazepines, side effects, in the intensive care unit, 498-500
- for status epilepticus, toxic effects, 525
- Bicarbonate, for diabetic ketoacidosis, 105
- Bile acid sequestrants, for thyrotoxicosis, 66
- Biphosphonates, for severe hypercalcemia, 179, 181-183
- Bipyridines, in the intensive care unit, 599-602
- Bites. See specific types, e.g., *Snake bites*.
- Bleeding, heparin and, 818
 heparin-induced, 534-535
 thrombolytic-induced, 545-548
 warfarin-induced, 539-541
- β -Blockers, epinephrine effects on, 591
- Blood, artificial, in the intensive care unit, toxic effects, 720-721
- Blood pressure, in pregnancy, 764-765
- Blood volume, in pregnancy, 763-764
- Blunt trauma, branch chain decision tree for, 384-387
 treatment, 410-412
- Botulism, *Clostridial*, 446-447
 immunoglobulins for, 701-702
- Bradycardia, fetal heart rate, obstetric conditions associated with, 921
- opioids and, 622
- Brain edema, pregnancy-induced hypertension and, 843-844
- Bretylium, and gastrointestinal upset, 513
- British Association for Immediate Care (BASICS), 263
- British Red Cross Society, 263
- Bronchodilators, in the intensive care unit, toxic effects, 639-657
 monitoring, 648-651
- Bronchospasm, acute, sympathomimetic agents for, 641
 magnesium for, 684
 treatment, monitoring, 648-651
- Budd-Chiari syndrome, acute fatty liver of pregnancy versus, 804
- Burns, chemical, patient care following, 302
 following disasters, management, 374-375
 treatment, 412
 victims of, immunoglobulin deficiency in, 699
- Cachectin, in the intensive care unit, toxic effects, 707
- Calcitonin, for severe hypercalcemia, 179, 183-184
- Calcitriol, insufficiency of, hypocalcemia due to, 194-195
- Calcium, chelation, hypocalcemia due to, 194-195
 for hyperkalemia, 169-170
 for hypermagnesemia, 220-221
 indications and dosing guidelines, 676-677

- Calcium (*Continued*)
in intensive care unit patients, 673-675
measurement of, 192
in physiologic activities, 192-194
physiologic function and homeostasis, 673
precipitation, hypocalcemia due to, 194-195
regulation of, 193-194
side effects, 675-676
Calcium antagonists, for thyrotoxicosis, 66
Calcium channel blockers, overdose of, calcium for, 675, 677
for pheochromocytomas, 13
Calcium-parathyroid axis, magnesium effects on, 122
Captopril, and acute interstitial nephritis, 569-570
and angioedema, 570
cardiovascular system effects, 566
cutaneous reactions to, 571
and neutropenia, 571-572
respiratory system effects, 567-568
Carbamazepine CNS effects, 528
renal disease and, 522
Carbimazole, for thyrotoxicosis, 64
Carbohydrate metabolism, disaster-related, 455-456
Carbohydrates, and liver function, 731-732
neonatal effects, 726
respiratory system effects, 727
Cardiac arrest, calcium for, 674-675, 677
Cardiac output, description, 765-766
in pregnancy, 765-766
Cardiomyopathy, congestive, hypophosphatemia due to, 207-208
peripartum, 789-790
Cardiopulmonary resuscitation (CPR), disaster-related, 472
following penetrating injuries, 409
Cardiorespiratory system, pregnancy and, 763-775
Cardiovascular system, angiotensin converting enzyme inhibitor effects on, 566
anticholinergic effects on, 643
corticosteroid effects on, 647
fetal, physiology of, 917-918
hemorrhage in, warfarin-induced, 541
magnesium effects on, 218-219
opioid effects on, 621-622
sympathomimetic agent effects on, 640-641
Catecholamines, 5-8
adrenergic-receptor activation by, hemodynamic effects, 585
biosynthesis and metabolism, 5-8
chemical structure of, 583, 584
drug interactions with, 591
effect on internal potassium balance, 159
in the intensive care unit, 583-599
and internal potassium balance, 157
mechanism of action, 584-586
Catheters, infections related to, parenteral nutrition-associated, 739-744
Central nervous system (CNS), abnormalities of, hypophosphatemia due to, 208
amrinone effects on, 601
anticholinergic effects on, 643
anticonvulsant effects on, 528-529
corticosteroid effects on, 647
digitalis toxic effects on, 603
dobutamine effects on, 598
dopamine effects on, 592
epinephrine effects on, 587
hemorrhage in, warfarin-induced, 540-541
isoproterenol effects on, 596-597
methylxanthine effects on, 645-647
norepinephrine effects on, 595
opioid effects on, 616-618
parenteral nutrition-associated toxic effects on, 726
sympathomimetic agent effects on, 640
tumors of, diabetes insipidus due to, 120
Cervical spine, immobilization of, following blunt trauma, 411
following disasters, 330
Chemical warfare agents, 307-315
meteorologic conditions affecting, 316
organization and defense preparations against, 316-317
Chemotherapy, in ectopic pregnancy, 910-911
Chest, trauma to, complications, 386
diagnostic procedures, monitoring, and treatment, 387
Cheyhabinsk, rail disasters in, anesthesia management in, 359
Children, in disasters, extrication, 465
planning, 468-469
rehabilitation, 468
response to, 465-468
transportation, 468
treatment, 463-470
equipment, 469
primary, 466-467
triage for, 467
vital signs, 467
Chloral hydrate, side effects, in the intensive care unit, 501-502
Chloride, indications and dosing guidelines, 671-672
physiologic function and homeostasis, 669-670
side effects, 670-671
Chlorpropamide, for diabetes insipidus, 122
hypoglycemia due to, 75-77

- Cholestasis, acute fatty liver of pregnancy versus, 803
- Civilian Military Contingency Hospital System (CMCHS), 262
- Civilian Reserve Air Fleet, 262
- Clostridial infections, in disaster victims, 442-443
- CNS. See *Central nervous system*.
- Coagulation, in pregnancy, changes in, 810-812
- Coagulopathy, postpartum hemorrhage due to, 886
- Cocaine, abuse, and abruptio placentae, 868
- Colloids, in the intensive care unit, toxic effects, 713-723
- Colony stimulating factors, in the intensive care unit, toxic effects, 707-708
- Coma, myxedema. See *Myxedema coma*.
- Computed tomography (CT), in acute fatty liver of pregnancy, 800
- in pheochromocytomas, 11-12
- Congestive heart failure, effect on antiarrhythmic agents, 510
- in thyrotoxic patients, treatment, 68
- Continuous ambulatory peritoneal dialysis (CAPD), following crush injury in seismic disasters, 429
- Continuous arteriovenous hemodialysis (CAVHD), following crush injury in seismic disasters, 429-430
- Continuous arteriovenous hemofiltration (CAVH), following crush injury in seismic disasters, 429-430
- Corticosteroids, administration and dosing, 647
- monitoring, 650-651
- for thyrotoxicosis, 64-65
- toxic effects, 647-648
- Cough, angiotensin converting enzyme inhibitors and, 567
- Coumarin, in pregnancy, 819-820
- Crush injury, following disasters, 328
- renal failure following, 421-435
- clinical presentation, 423
- management, 424-426
- in seismic disasters, dialytic therapy for, 426-431
- Cyanide poisoning, nitroprusside-induced, diagnosis, 559-560
- pathophysiology, 555-557
- prevention, 559
- toxic doses, 557-559
- treatment, 560
- Cyclones (hurricanes, typhoons), 276-278
- Cytokines, in the intensive care unit, toxic effects, 706-707
- Dead bodies, disposition of, following natural disasters, 287
- Defibrillator, portable, in disaster anesthesia, 345
- Desmopressin, for diabetes insipidus, 122
- Dexamethasone, in adrenocortical failure, 37-39
- for thyrotoxicosis, 64-65
- Dexmedetomidine, for opioid-induced muscle rigidity, 621
- Dextran, in the intensive care unit, toxic effects, 719-720
- Dextrose, for hypoglycemia, 84-85
- Diabetes, in pregnancy, and shoulder dystocia, 853
- Diabetes insipidus, 109-125
- case study, 109
- causes, 118-121
- diagnosis, physiologic, 116-119
- differential diagnosis, 114-116
- manifestations, 114-116
- treatment, 121-123
- Dialysis, for crush injury in seismic disasters, 426-432
- for hypercalcemia, 179, 185-186
- for hyperkalemia, 169-171
- Diazepam, for status epilepticus, toxic effects, 525
- Diethylstilbestrol (DES), ectopic pregnancy induced by, 902-903
- Digibind, in digitalis toxicity, 606-608
- Digitalis Fab fragments, in digitalis toxicity, 607
- Digitalis glycosides, in the intensive care unit, 602-608
- Digoxin, adverse effects, 603-605
- drug interactions with, 605-606
- overdose of, immunoglobulins for, 704-705
- toxic effects, 606-608
- Dipyridamole, for heparin-induced bleeding, 536
- Disasters, anesthesia for, 339-361. See also *Anesthesia, for disaster victims*.
- bilateral aid for, 267
- children in, planning, 468-469
- treatment, 463-470
- critical care team responsibilities in, 364
- definition, 271, 293-294, 437
- evacuation and transport following, 333-334
- extrication following, 332
- fluid resuscitation in, clinical algorithm in, 363-381
- branch chain logic, 365-366
- hospital involvement in, 294
- infections in, 437-450
- recommendations, 448-449
- injuries associated with, 372-377
- manmade, 293-319

DDAVP (1-desamino-8-D-arginine vasopressin), for diabetes insipidus, 121-122

Disasters (*Continued*)

- chemical warfare agents, 307-315
- field medical treatment following, 296-297
- hazardous materials, 300-305
- versus natural, 294
- nature of, 295
- patient flow following, 297-299
- patient triage following, 297
- terrorism, 306-307
- victims of, 295-296
- mass, critical care medicine in, 417-419
 - definition, 293-294
 - field management and critical care, patient care in, 405-416
 - triage factors, 403-404
 - field management in, 401-420
- medical care following, 326-332
 - availability of, 438-439
 - issue on, 257-484
 - nutritional and metabolic, 451-461
 - preventive, failure of, 439-440
- medical equipment and supplies in, 333
- mortality, 272
- natural, 271-292
 - cyclones, 276-278
 - description, 271
 - earthquakes, 282-286
 - floods, 274-276
 - health problems associated with, 287-288
 - versus manmade, 294
 - in the 1900s, 272-273
 - short-term effects, 285
 - tornadoes, 278-280
 - volcanoes, 280-282
 - nutritional and metabolic support following, 451-461
- organizations, 257-270
 - in Denmark, 264
 - in France, 263-264
 - international, 257-265
 - in Israel, 264-265
 - nongovernmental and private, 267-268
 - review of disaster management and future disaster planning, 268-269
 - in Sweden, 264
 - in the Union of Soviet Socialist Republics, 265
 - in the United Kingdom, 263
 - in the United States, 258-262
 - civilian, 258-260
 - military, 260-262
- patient transfer following, 416-417
- planning, 339-341
 - role of ICU personnel in, 299
- prediction of, 265-267
- prehospital and hospital response in, assessment, 471-484
 - evaluation design and data collection instruments in, 479-480

- evaluation team in, 478-479
- methodologic approach, 473-478
- disaster plan, 473-478
- renal failure in, 421-435. See also *Kidney, failure of, in disasters*.
- dialytic therapy for, 426-432
- response teams in, 321-323
- resuscitation problems following, 364-365
- scene of, considerations, 324-325
- search, rescue, and evacuation following, 321-337
- training for, 334-335
- types, 464
- victims of, alterations in, 438
- Disseminated intravascular coagulation, in abruptio placentae, 872-873
- Diuretics, hypophosphatemia due to, 204-205
 - loop, for hypercalcemia, 179, 184
 - for hyponatremia, 138-139
 - thiazide, for diabetes insipidus, 123
- Dobutamine, adverse effects, 598-599
 - clinical pharmacology, 598
- Dopamine, adverse effects, 592-594
 - clinical pharmacology, 592
 - drug interactions with, 594
 - monitoring, 594
- Drugs, experimental, for hypercalcemia, 186
 - hyperkalemia due to, 162, 164
 - hypomagnesemia due to, 230-231
 - intensive care unit, toxic effects, issue on, 489-753
 - pharmacokinetics, altered, parenteral nutrition-associated, 744-745
 - for thyrotoxicosis, 63-66
- Dysgeusia, angiotensin converting enzyme inhibitors and, 572-573
- Dysrhythmia. See *Arrhythmia*.
- Dystocia, shoulder, 851-856
 - definition, 852
 - incidence, 851-852
 - management, 855-858
 - McRoberts maneuver in, 855, 856
 - morbidity, 852-853
 - predisposing factors, 853-854
 - prevention, 854-855
 - Zavanelli maneuver in, 856, 858
- Earthquakes, 282-286
 - in Armenia, anesthesia management in, 356-358
 - injuries from, 284-286
 - tectonic plates and, 283
- Eclampsia, in acute fatty liver of pregnancy, 800
 - pregnancy-induced hypertension and, 841
- Edema, cerebral. See *Brain edema*.
- pulmonary. See *Pulmonary edema*.

- Eisenmenger syndrome, pregnancy and, 781-783
- Electrocardiography (ECG), in pulmonary thromboembolism, in pregnancy, 815
- Electrolytes, administration of, in the intensive care unit, 659-693
- Embolism, amniotic fluid, 877-882
clinical presentation, 877-878
description, 877
diagnosis, 880
pathophysiology, 878-880
treatment, 880-881
- Embolization, angiographic, in postpartum hemorrhage, 894
- Emergency medical service, in manmade disasters, 296-297
- Encephalomyopathies, mitochondrial, anticonvulsants for, toxic effects, 524
- Encephalopathies, drug-induced, seizures caused by, anticonvulsants for, toxic effects, 524
- Endocarditis, bacterial, prophylaxis, 787
- Endocrine crisis, issue on, 1-252
- Endotoxin, toxicity of, immunoglobulins for, 700-701
- Energy metabolism, during fasting, 452-453
during hypermetabolic/hypercatabolic states, 453-454
- Energy needs, evaluation, 454-455
- Envenomations, immunoglobulins for, 703-704
- Environmental exposure, following natural disasters, 287
- Eosinophilia, parenteral nutrition—associated toxic effects on, 738
- Epidemics, following natural disasters, 287
- Epinephrine, adverse effects, 587-592
clinical pharmacology, 586-587
infusion of, monitoring, 591-592
- Ethanol, toxic effects, nitroglycerin-induced, 564
- Etidronate, for hypercalcemia, 182
- Extremities, trauma to, following disasters, management, 376-377, 412-416
- Eyes, anticholinergic effects on, 644
- Fallopian tubes, inflammatory disease of, ectopic pregnancy induced by, 902
physiology, 900
- Fasting, energy metabolism during, 452-453
- Fat emulsions, liver function effects, 732
neonatal effects, 726
respiratory system effects, 728-729
- Fat metabolism, disaster-related, 456
- Fatty liver, acute, of pregnancy, 799-808
Budd-Chiari syndrome versus, 804
case study, 805-806
causes, 799
- cholestatitis of pregnancy versus, 803
clinical presentation, 799, 800
diagnosis, 802-804
HELLP syndrome versus, 802-803
hemolytic uremic syndrome versus, 803
hepatitis versus, 803
laboratory studies, 800-801
liver biopsy, 801-802
pathogenesis, 799-800
SLE versus, 803-804
thrombotic thrombocytopenic purpura versus, 803-804
transplantation in, 804
treatment, 804
- Fetal asphyxia, intrauterine, 920
- Fetal distress, definition, 845
pregnancy-induced hypertension and, 845
- Fetal heart, neurologic control of, 918-919
- Fetal heart rate, changes in, obstetric conditions associated with, 921-925
accelerations, 922-923
decelerations, 923-924
sinusoidal pattern, 922
- Fetal monitoring, in critical illness, 920-925
- Fetus, abruptio placentae effects on, 873-874
acid-base assessment, obstetric conditions associated with, 924-925
cardiovascular physiology, 917-918
delivery of, in pregnancy-induced hypertension, 837
- Fibrinogen scanning, 1251, in venous thrombosis, in pregnancy, 814
- Fires, following floods, 275
- Floods, 274-276
- Fluid resuscitation, colloids in, 713-723
in disasters, clinical algorithm in, 363-381
decision tree for, 367-372
- Fluids, for diabetic ketoacidosis, 107-108
effects on respiratory system, 726-727
- Food poisoning, *Clostridial*, 446-447
- Forward Army Surgical Team, 262
- Fractures, open, following disasters, management, 377
- Furosemide, for hypercalcemia, 184
for hyperkalemia, 169-170
- Gallium nitrate, for hypercalcemia, 186
- Gastric erosion, NSAIDs and, 630
- Gastrointestinal infections, disaster-related, 445-447
- Gastrointestinal system, amrinone effects on, 602
antiarrhythmic agent effects on, 513
anticholinergic effects on, 644
anticonvulsant effects on, 523
corticosteroid effects on, 648
digitalis toxic effects on, 603

Gastrointestinal system (*Continued*)

- epinephrine effects on, 590
 - hemorrhage in, warfarin-induced, 539-540
 - methylxanthine effects on, 646-647
 - opioid effects on, 622-623
 - parenteral nutrition—associated toxic effects on, 730
 - sympathomimetic agent effects on, 642
- Gelatin, in the intensive care unit, toxic effects, 718-719
- Genital tract, lower, lacerations of, postpartum hemorrhage due to, 884, 885
- Genitourinary system, anticholinergic effects on, 644
- hemorrhage in, warfarin-induced, 541
- Glucagon, effect on internal potassium balance, 160
- Glucocorticoids, for hypercalcemia, 179, 184-185
- physiology and regulation of, 25-27
 - for thyroid storm, 66-67
- Glycosides, hypomagnesemia due to, 230
- Gonorrhea, ectopic pregnancy induced by, 902
- Granulocytic function, parenteral nutrition—associated toxic effects on, 736-737
- Graves' disease, and hypothyroidism, 47-48
- Hazardous material disasters, 300-305
- patient care following, 301-305
- Head injuries, disaster-related, in children, 466-467
- management, 375-376
 - treatment, 412-416
- Heart, amrinone effects on, 601
- digitalis toxic effects on, 603-605
 - dobutamine effects on, 598-599
 - dopamine effects on, 592-593
 - epinephrine effects on, 587
 - fetal, changes in, 921-925
 - isoproterenol effects on, 597
 - norepinephrine effects on, 595
 - surgery of, pregnancy and, 793-794
 - valves of, artificial, pregnancy and, anticoagulation for, 792-793
- Heart disease, anticonvulsant-induced, 522-523
- congenital, pregnancy and, 778-784. *See also* specific disorders.
 - fetal considerations, 784
 - physiologic considerations, 778-784
 - pregnancy and, 777-779
 - counseling for, 777-778
 - rheumatic, pregnancy and, 784-788
- Heart rate, in pregnancy, 765
- Heart valve, artificial, thromboembolic disorders and, 823
- HELLP. *See Hemolysis, elevated liver enzymes, and low platelet count.*
- Hematoma, evacuation of, in postpartum hemorrhage, 891-892
- pulmonary, warfarin-induced, 541
- Hemodialysis, following crush injury in seismic disasters, 429
- Hemolysis, elevated liver enzymes, and low platelet count (HELLP), acute fatty liver of pregnancy versus, 802-803
- pregnancy-induced hypertension and, 840-841
 - parenteral nutrition—associated toxic effects on, 737-738
- Hemolytic uremic syndrome, acute fatty liver of pregnancy versus, 803
- Hemorrhage, in amniotic fluid embolism, 878
- heparin-induced, 534-535
 - postpartum, 883-897
 - causes, 884-886
 - definition, 883
 - diagnosis, 886-889
 - incidence, 883
 - management, 888-895
 - medical, 889-891
 - surgical, 891-895
 - prevention, 886
 - thrombolytic-induced, 545-548
 - warfarin-induced, 539-541
- Heparin, adverse effects, 534-538
- bleeding due to, 818
 - dosage, 534
 - indications, 533-534
 - mechanism of action, 533
 - osteoporosis due to, 818
 - in pregnancy, 816-819, 821-823
 - in artificial heart valve patients, 792-793
 - thrombocytopenia due to, 818
- Hepatitis, acute fatty liver of pregnancy versus, 803
- Hetastarch, in the intensive care unit, toxic effects, 716-718
- Histiocytosis X, diabetes insipidus due to, in children, 120
- Hurricanes, 276-278
- Hugo, deaths attributed to, 277
- Hydralazine, in pregnancy-induced hypertension, 835-836
- Hydrocortisone, in adrenocortical failure, 37-39
- Hypercalcemia, phosphate for, 679

- saline infusions for, 662
- severe, 175-190
 - case study, 175
 - causes, 178
 - manifestations, 176-179
 - mechanisms of, 176-179
 - treatment, 179, 180-187
- steroids for, 697
- Hyperglycemia, corticosteroids and, 648**
 - in diabetic ketoacidosis, 93-95
 - sympathomimetic agents and, 642
- Hyperkalemia, 155-174**
 - calcium for, 675, 677
 - case study, 155
 - diagnosis, 166-168
 - drug-induced, 162, 164
 - heparin-induced, 537
 - management, 168-171
 - manifestations, 165-166
 - succinylcholine-induced, 492
 - treatment, 668
- Hypermagnesemia, 215-223**
 - cardiovascular effects, 218-219
 - case study, 215-216
 - causes, 217-218
 - clinical manifestations, 218-219
 - diagnosis and treatment, 220-221
 - neuromuscular effects, 219
 - pathophysiology, 216-217
 - saline infusions for, 662
- Hyperosmolarity, effect on internal potassium balance, 160**
- Hyperparathyroidism, and hypercalcemia, 178**
- Hyperphosphatemia, 209-212**
 - causes, 209
 - clinical consequences, 211
 - endogenous sources for, 210
 - exogenous sources for, 210-211
 - of renal failure, 209-210
 - treatment, 211-212
- Hypersensitivity, amrinone and, 602**
 - digoxin and, 605
 - parenteral nutrition—associated toxic effects on, 738-739
 - thrombolytic-induced, 547
- Hypertension, intracranial, saline infusions for, 662**
- pheochromocytomas due to, 8-9**
- pregnancy-induced, 829-850**
 - and abruptio placentae, 844-845, 866-868
 - in acute fatty liver of pregnancy, 800
 - causes, 829-830
 - cerebral edema in, 843-844
 - complications, 838-845
 - diagnosis, 830-831
 - eclampsia in, 841
 - evaluation, 831-832
 - fetal delivery in, 837
 - fetal distress in, 845
 - HELLP in, 840-841
 - hemodynamic monitoring in, 836-837
 - oliguria in, 839-840
 - pulmonary edema in, 842-843
 - refractory hypertension in, 838-839
 - treatment, 831-837
 - antihypertensive, 835-836
 - fluid, 834
 - narcotics, 836
 - seizure prophylaxis, 834-835
 - pulmonary, pregnancy and, 781-783
 - refractory, pregnancy-induced hypertension and, 838-839
- Hyperthermia, malignant, succinylcholine-induced, 493**
- Hyperthyroidism, and hypermagnesemia, 230**
 - "true", definition, 58
- Hypertonic saline, for hyponatremia, 139-140**
- Hypoadosteronism, ACE inhibitor-induced, 572**
 - hyporeninemic, 161-162
 - isolated, 31
- Hypocalcemia, 191-200**
 - calcium for, 673-674, 676-677
 - case study, 191-192
 - causes, 194-196
 - clinical manifestations, 674
 - in critically ill patients, causes, 674
 - magnesium for, 684
 - signs and symptoms, 196-197
 - treatment, 197-199
- Hypochloremia, causes, 671**
 - chloride for, 670
- Hypoglycemia, 75-87**
 - angiotensin converting enzyme inhibitors and, 572
 - anticonvulsants for, toxic effects, 524
 - case study, 75-76
 - causes, 78-79
 - definition, 76
 - diagnosis, 82-84
 - laboratory studies, 81-82
 - pathophysiology, 76-77
 - physical examination, 80-81
 - signs and symptoms, 79-80
 - treatment, 84-86
- Hypokalemia, 143-153**
 - cardiac effects, 148-149
 - case study, 143
 - clinical features, 148-150
 - corticosteroids and, 648
 - evaluation, 146
 - musculoskeletal effects, 150
 - nonredistribution, 147-148
 - pathophysiology, 144
 - potassium for, 666-669
 - redistribution, 145-147

- Hypokalemia** (*Continued*)
 renal effects, 149-150
 signs and symptoms, 666
 sympathomimetic agents and, 642
 theophylline-induced, 647
 treatment, 150-152
- Hypomagnesemia**, 225-252
 case study, 225-256
 causes, 227-231, 683
 clinical manifestations, 238-241, 684
 diagnosis, 234-238
 magnesium for, 682-684, 685-686
 pathophysiology, 231-234
 treatment, 242-245
- Hyponatremia**, 127-142
 acute, management, 134-136
 acute versus chronic, 133-134
 case studies, 127
 chronic, causes, 137
 management, 136-139
 consequences of, 131-132
 hypotonic, causes, 129
 and myxedema coma, 44-45
 nonhypotonic, causes, 129
 pathogenesis, 128-131
 rapid correction of, dangers of, 132-133
 rapid onset of, dangers of, 132
 saline infusions for, 660-661, 663-665
- Hypophosphatemia**, 203-209
 causes, 203-206
 clinical consequences, 206-208
 clinical manifestations, 679
 and hypercalcemia, 185
 phosphate for, 678-679, 680-682
 sympathomimetic agents and, 642
 treatment, 208-209
- Hypothermia**, following disasters, 331
 opioids and, 618
- Hypothyroidism**, causes, 45-46
 Graves' disease and, 47-48
 and myxedema coma, 43-56
- Hysterectomy**, in postpartum hemorrhage, 893-894
- Idiopathic hypertrophic subaortic stenosis**, pregnancy and, 790-791
- Immobilization**, of cervical spine, following disasters, 330
 following blunt trauma, 411
- Immune system**, opioid effects on, 625
 parenteral nutrition—associated toxic effects on, 733-737
- Immunity**, cell-mediated, parenteral nutrition—associated toxic effects on, 735-736
- Immunoglobulins**, for botulism and tetanus, 701-703
 deficiency of, in the intensive care unit, 699-706
 for digitalis overdose, 704-705
 for envenomations, 703-704
 opsonic activity of, 699-700
 in organ transplantation, 705-706
 in protection against endotoxin, 700-701
- Inappropriate ADH syndrome**, anticonvulsant effects on, 529
- Infection**, parenteral nutrition—associated, 742-744
- Infections**, disaster-related, 437-450
 in noninjured patients, 444-448
- Inflammatory response**, acute, parenteral nutrition—associated toxic effects on, 736-737
- Inotropic agents**, in the intensive care unit, toxic effects, 583-613
- Insulin**, deficiency of, 163-164
 for diabetic ketoacidosis, 102-103
 effect on internal potassium balance, 157-159
 for hyperkalemia, 169-170
 hypoglycemic effects, 76-86
- Intensive care unit**, angiotensin converting enzyme inhibitors in, toxic effects, 565-573
 antiarrhythmic agents in, 507-520
 anticoagulants in, risks and benefits, 533-543
 anticonvulsant agents in, uses and side effects, 521-532
 bronchodilators in, toxic effects, 639-657
 colloids in, toxic effects, 713-723
 in disaster planning, 299
 drugs used in, toxic effects, issue on, 489-753
 electrolyte and trace mineral administration in, toxic effects, 659-693
 general anesthesia in, uses, 502
 immunoglobulins in, 699-706
 inotropic agents in, toxic effects, 583-613
 neuromuscular blocking agents in, uses and side effects, 489-498
 nitroglycerin in, toxic effects, 562-565
 opioids in, adverse effects, 615-628
 parenteral nutrition in, toxicities of, 725-753
 sedatives in, uses and side effects, 498-502
 steroids and biologic agents in, 695-711
 thrombolytics in, risks and benefits, 543-548
- Interferon**, in the intensive care unit, toxic effects, 706
- Interleukin-2**, in the intensive care unit, toxic effects, 706-707
- Intracranial pressure (ICP)**, increased, steroids for, 697

- succinylcholine-induced, 492
 - Intrauterine device, ectopic pregnancy induced by, 902
 - Intrauterine growth retardation, abruptio placentae and, 874
 - Iodine, for thyrotoxicosis, 64
 - Ipratropium bromide, CNS effects, 643
 - Isoproterenol, adverse effects, 596-597
 - clinical pharmacology, 596
 - drug interactions with, 597
 - monitoring, 597-598
 - Isotonic saline, for hyponatremia, 138
 -
 - Johnson maneuver, in uterine inversion, 860
 -
 - Kayexalate, for hyperkalemia, 169-170
 - Ketamine, adverse effects, 629
 - in disaster anesthesia, 352
 - dosing guidelines, 629-630
 - drug interactions with, 629
 - in the intensive care unit, 629-630
 - Ketoacidosis, diabetic, 89-108
 - case studies, 89-92
 - epidemiology, 96-97
 - hyperglycemia due to, 93-95
 - hypophosphatemia due to, 204, 206
 - ketogenesis in, 95-96
 - pathophysiology, 92-96
 - laboratory abnormalities, 99-100
 - precipitating factors, 97-98
 - signs and symptoms, 98-99
 - treatment, 100-105
 - Ketogenesis, in diabetic ketoacidosis, 95-96
 - Ketorolac, adverse effects, 630
 - Kidney, angiotensin converting enzyme inhibitor effects on, 568-570
 - epinephrine effects on, 589
 - failure of, antiarrhythmic agent effects on, 509
 - in disasters, 421-435
 - clinical presentation, 423
 - dialysis for, 426-431
 - clinical approach, 431-432
 - epidemiology, 421-423
 - management, 424-426
 - mobilization response, 432-433
 - hyperphosphatemia and, 209-210
 - hypokalemic effects, 149-150
 - norepinephrine effects on, 595
 - parenteral nutrition—associated toxic effects on, 733
- Kidney disease, anticonvulsant-induced, 522
-
- Labetalol, for pheochromocytomas, 13
- Labor and delivery, abruptio placentae and, 871
 - third stage, management, 886-887
- Laparoscopy, in ectopic pregnancy, 909-910
- Leukemia, lymphocytic, immunoglobulin deficiency in, 700
- Lidocaine, for arrhythmias in the intensive care unit, 507-508
 - congestive heart failure effects, 510
 - and gastrointestinal upset, 513
 - neurologic toxicity due to, 512-513
 - proarrhythmic effects, 511
- Lithium, for thyrotoxicosis, 65
- Liver, dysfunction of, anticonvulsant-induced, 522
 - in the intensive care unit, effect on antiarrhythmic agents, 509-510
- fatty. *See Fatty liver.*
- parenteral nutrition—associated toxic effects on, 730-733
 - rupture of, pregnancy-induced hypertension and, 841-842
- Liver failure, anticonvulsants and, 527
- Liver transplantation, acute fatty liver of pregnancy versus, 804
- Loop diuretics, for hypercalcemia, 179, 184
 - for hyponatremia, 138-139
- Lorazepam, for status epilepticus, toxic effects, 525
- Lung scanning, perfusion, in pulmonary thromboembolism, in pregnancy, 815-816
- Lupus-like syndrome, anticonvulsant-induced, 528
-
- Magnesium, indications and dosing guidelines, 685-686
 - in intensive care unit patients, 682-684
 - physiologic function and homeostasis, 682
 - in preeclamptic seizure prophylaxis, 834-835
 - repletion of, management, 242-245
 - side effects, 684-685
- Magnetic resonance imaging (MRI), of pheochromocytomas, 12
- Malnutrition, following disasters, nutritional support for, 460
 - protein calorie, hypomagnesemia due to, 227-229
- Marfan's syndrome, description, 791-792
- pregnancy and, 791-792
- Mass casualty incident, definition, 293-294
- McRoberts maneuver, in shoulder dystocia, 855, 856

- Mental illness, in thyrotoxic patients, treatment, 68
- Meperidine, CNS effects, 617-618
- Metabolism, corticosteroid effects on, 648
- digitalis toxic effects on, 605
 - dopamine effects on, 593-594
 - epinephrine effects on, 590
 - isoproterenol effects on, 597
 - methyloxanthine effects on, 647
 - norepinephrine effects on, 595
 - sympathomimetic effects on, 642
- Metaproterenol, for acute bronchospasm, 641
- Methemoglobinemia, nitroglycerin-induced, 562-564
- Methotrexate, in ectopic pregnancy, 910
- α -Methylparatyrosine, for pheochromocytomas, 13
- Methylprednisolone, administration and dosing, 647
- toxic effects, 647-648
- Methyloxanthines, administration and dosing, 644-645
- monitoring, 649-650
 - toxic effects, 645-647
- Midazolam, side effects, in the intensive care unit, 499-500
- Mineralocorticoids, physiology and regulation of, 27-28
- Mitral valve, insufficiency of, pregnancy and, 786-787
- stenosis of, PCWP in, intrapartum alterations in, 785-786
 - pregnancy and, 785-787
- Monocyte/macrophage function, parenteral nutrition—associated toxic effects on, 736
- Morphine, adverse effects, 631
- following disasters, 331
- Multiparity, grand, and abruptio placentae, 867
- Munchausen's syndrome, warfarin overdosage and, 542
- Muscle pain, succinylcholine-induced, 493
- Muscle rigidity, opioid-induced, 620-621
- Muscle tremor, sympathomimetic agents and, 642
- Musculoskeletal system, hypokalemic effects, 150
- Myeloma, multiple, immunoglobulin deficiency in, 700
- Myocardial infarction, pregnancy and, 792
- Myxedema coma, 43-56
- case study, 43-44
 - clinical characteristics, 46
 - definition, 44
 - diagnosis, 49-51
 - history, 46-47
 - laboratory studies, 48-49
 - pathophysiology, 44-45
 - physical examination, 47-48
 - treatment, 51-53
- N-acetylprocainamide (NAPA), effect of renal failure on, 509
- Naloxone, in disaster anesthesia, 353
- Narcotics. *See Opioids.*
- National Disaster Medical System, 259-260
- Nausea and vomiting, opioids and, 618
- Neonates, parenteral nutrition—associated toxic effects on, 725
- Nephritis, interstitial, captopril and, 569-570
- Nernst equation, 144
- Neuromuscular blocking agents, depolarizing, 490-494
- indications, 490
 - nondepolarizing, 494-498
 - acid-base abnormalities and, 497
 - antibiotics, effects on, 497
 - duration of action, 494-495
 - intermediate-duration, 496
 - metabolism, 495
 - neuromuscular monitoring with, 494
 - pharmacologic reversal, 497-498
 - routes of excretion, 495
 - side effects, 495
 - toxic effects, 489-498
 - combination treatment, 496-497
- Neuromuscular system, magnesium effects, 219
- Neutropenia, angiotensin converting enzyme inhibitors and, 571-572
- Nitrogen balance, disaster-related, 455
- Nitroglycerin, adverse effects, 565
- toxic effects, 562-565
 - ethanol intoxication, 564
 - methemoglobinemia, 562-564
 - propylene glycol, 564-565
- Nitroprusside, toxic effects, 555-562
- cyanide poisoning, 555-560
 - thiocyanate toxicity, 560-562
- Nitrous oxide, in disaster anesthesia, contraindications, 354
- Nitrous oxide/oxygen combination, following disasters, 331
- Nonsteroidal anti-inflammatory drugs (NSAIDs), adverse effects, 630-631
- dosing guidelines, 632
 - drug interactions with, 631-632
 - in the intensive care unit, 630-632
- Norepinephrine, adverse effects, 595-596
- clinical pharmacology, 594-595
 - drug interactions with, 595-596
 - monitoring, 596
- NSAIDs. *See Nonsteroidal anti-inflammatory drugs.*

- Nutrition, parenteral. See *Parenteral nutrition*.
- Nutritional support, of critically ill patients, 457-458
 following disasters, 451-461
 recommendations, 459-460
 routes of administration, 458-459
- Obesity, in shoulder dystocia, 853
- Obstetrics, emergencies in, issue on, 763-928
- Oliguria, definition, 839
 pregnancy-induced hypertension and, 839-840
- Opioid receptors, adverse effects, 615-625
- Opioids, in disaster anesthesia, 353
 dosing guidelines, 628
 drug interactions with, 627-628
 in the intensive care unit, administration of, 626-627
 toxic effects, 615-628
 in pregnancy-induced hypertension, 836
- Organophosphates, in chemical warfare, 310-315
- Osteoporosis, heparin-induced, 537, 818
- Oxygen, in disaster anesthesia, 348-349
- Oxygen consumption, epinephrine effects on, 587-588
- Oxygenation, placental, 919-920
- PAC system, in disaster anesthesia, 347-348
- Paget's disease, AHPBP for, 182-183
- Pain, muscular, succinylcholine-induced, 493
- Pain control, following disasters, 331
- Pancreatitis, anticonvulsants and, 528
- Pancuronium bromide, in disaster anesthesia, 353-354
- Parathyroid hormone insufficiency, hypocalcemia due to, 194-195
- Parenteral water intoxication, 135-136
- Parenteral nutrition, altered drug pharmacokinetics in, 744-745
 catheter-associated toxicities in, 739-744
 CNS toxicities in, 726
 gastrointestinal toxicities in, 730
 hematologic toxicity in, 737-738
 hepatic toxicities in, 730-733
 hypersensitivity in, 738-739
 immunologic toxicities in, 733-737
 in the intensive care unit, toxicities of, 725-753
 pulmonary toxicities in, 726-730
 renal toxicities in, 733
- Patent ductus arteriosus, pregnancy and, 781
- PCWP. See *Pulmonary capillary wedge pressure*.
- Penetrating injuries, treatment, 407-410
- Pentastarch, in the intensive care unit, toxic effects, 720
- Peripheral nerve stimulator, in disaster anesthesia, 345
- Phenobarbital, effect of hepatic dysfunction on, 522
 effect of renal disease on, 522
 for status epilepticus, toxic effects, 526
- Phenoxybenzamine, for pheochromocytomas, 12-13
- Phenytoin, CNS effects, 528-529
 effect of cardiac disease on, 522-523
 effect of renal disease on, 522
 for status epilepticus, toxic effects, 525-526
- Pheochromocytoma, 1-21
 case study, 2-4
 clinical features, 8-12
 embryology, anatomy, and physiology, 4-8
 incidence, 8-9
 management, 12-19
 postoperative, 17-18
 in pregnancy, 18
 surgical, 17
 metastatic, management, 18-19
- Phosphate, for diabetic ketoacidosis, 104
 homeostasis, 202-203
 indications and dosing guidelines, 680-682
 in intensive care unit patients, 678-679
 physiologic function and homeostasis, 677-678
 side effects, 679-680
- Physical dependence, opioids and, 625
- Placenta, abruptio of. See *Abruptio placentae*.
 retained, postpartum hemorrhage due to, 885-886
- Placental oxygen exchange, 919-920
- Plasma protein fractions, in the intensive care unit, toxic effects, 718
- Plasma volume, in pregnancy, 763-764
- Plasmapheresis, for thyrotoxicosis, 66
- Platelets, aggregation of, dopamine effects on, 594
 norepinephrine effects on, 595
 function of, dobutamine effects on, 599
- Plethysmography, impedance, in venous thrombosis, in pregnancy, 813
- Plicamycin, for hypercalcemia, 179, 181
- Pneumatic antishock garment (PASC), following penetrating injuries, 408
- Poisoning, cyanide. See *Cyanide poisoning*.
 patient care following, 301-305
- Polydipsia, psychotic, management, 134-135

- Porphyria, acute intermittent, anticonvulsants for, 523-524
- Post-prostatectomy syndrome, management, 136
- Posture, in pregnancy, effects on maternal hemodynamics, 767, 768, 769
- Potassium, for diabetic ketoacidosis, 103-104
- homeostasis, 145-148
 - indications and dosing guidelines, 667-669
 - in intensive care unit patients, 666-667, 670
 - physiologic function and homeostasis, 665-666
 - side effects, 667
- Potassium balance, external, 157-158, 160
- disorders of, 160-163
 - internal, 157-160
 - disorders of, 163-164
- Potassium concentration, normal, 157
- Potassium homeostasis, normal, 156-160
- Prazosin, for pheochromocytomas, 13
- Preeclampsia. *See Hypertension, pregnancy-induced.*
- Pregnancy, abdominal trauma in, and abruptio placentae, 867
- acute fatty liver of, 799-808. *See also Fatty liver, acute, of pregnancy.*
 - amrinone effects on, 602
 - anticoagulants in, heparin, 816-819
 - complications, 818-819
 - oral, 819-820
 - prophylactic, 822-823, 824
 - therapeutic, 821-822
 - warfarin, 817
 - complications, 819
 - antithrombin III, deficiency in, 823
 - aortic stenosis in, 787-788
 - arrhythmias in, 793-794
 - artificial heart valves in, anticoagulation for, 792-793
 - atrial septal defect in, 780
 - blood pressure changes in, 764-765
 - blood volume changes in, 763-764
 - cardiac disease in, 777-797
 - congenital, 778-784
 - counseling for, 777-778
 - cardiac lesions in, 784-789
 - mitral stenosis, 785-786
 - pulmonic, 785
 - tricuspid, 785
 - cardiac output changes in, 765-766, 859
 - cardiorespiratory alterations during, 763-775
 - cardiovascular responses during, intrapartum hemodynamics in, 768-770
 - postpartum hemodynamics in, 771
 - cardiovascular surgery in, 794
 - coagulation changes during, 810-812
 - coarctation of the aorta in, 783
 - diabetes insipidus due to, 120
 - digitalis toxic effects on, 605
 - dopamine effects on, 594
 - ectopic, 899-915
 - causes, 900-903
 - diagnosis, 903-906
 - histopathology, 906-907
 - historical background, 899
 - incidence, 899-900
 - mortality in, maternal, 911
 - subsequent pregnancy outcome, 911
 - treatment, 907-911
 - Eisenmenger syndrome in, 781-782
 - emergencies in, issue on, 763-928
 - epinephrine effects on, 590
 - fetal monitoring in, 920-925
 - heart rate in, 765
 - hypertension in, and abruptio placentae, 866-868
 - idiopathic hypertrophic subaortic stenosis in, 790-791
 - isoproterenol effects on, 597
 - late, cardiovascular responses during, antepartum hemodynamic values in, 768
 - liver enzymes in, elevated, differential diagnosis, 833
 - Marfan's syndrome in, 791
 - mitral insufficiency in, 787
 - mortality rates, 778
 - myocardial infarction in, 792
 - norepinephrine effects on, 595
 - patent ductus arteriosus in, 781
 - peripartum cardiomyopathy in, 789-790
 - pheochromocytomas in, management, 18
 - plasma volume increase in, 763-764
 - posture during, effects on maternal hemodynamics, 767, 768, 769
 - preeclampsia in, 829-850. *See also Hypertension, pregnancy-induced.*
 - protein C or S deficiencies in, thromboembolic disorders and, 823
 - pulmonary embolism in, 809-828. *See also Pulmonary embolism, in pregnancy.*
 - pulmonic stenosis in, 784
 - respiratory changes during, 771-772
 - stroke volume changes in, 765-766
 - systemic vascular resistance in, 766-767
 - tetralogy of Fallot in, 783-784
 - thromboembolic disorders in, 809-828
 - thromboembolism in, pulmonary, 814-816

- septic pelvic, 823-824
- thrombosis in, ovarian vein, 823-824
- venous, 812-814
- in thyrotoxic patients, 68
- ventricular septal defect in, 780-781
- warfarin during, adverse effects, 542
- Primidone, CNS effects, 528
- effect of renal disease on, 522
- Procainamide, for arrhythmias in the
 - intensive care unit, 508
 - in congestive heart failure, 510
 - in hepatic dysfunction, 509-510
 - in renal failure, 509
- Propofol, side effects, in the intensive care unit, 500
- Propranolol, for thyrotoxicosis, 63, 65
- Propylene glycol, toxic effects, nitroglycerin-induced, 564-565
- Propylthiouracil, for thyrotoxicosis, 63-64
- Prostaglandin synthesis inhibitors, for hypercalcemia, 185
- Prosthetic valves, heart, pregnancy and, anticoagulation for, 792-793
- Protamine, for heparin-induced bleeding, 535
- Protein, C, deficiency of, in pregnancy, 823
 - effects on liver function, 732-733
 - effects on respiratory system, 729-730
- S, deficiency of, in pregnancy, 823
- Proteinuria, angiotensin converting enzyme inhibitors and, 568
- Pseudocholinesterase, atypical, succinylcholine-induced, 492
- Pulmonary capillary wedge pressure (PCWP), mitral stenosis and, intrapartum alterations in, 785-786
- Pulmonary edema, pregnancy-induced hypertension and, 842-843
- Pulmonary embolism, in pregnancy, 809-828
 - incidence, 809-810, 811
 - risk factors, 811
 - treatment, 820-821
- Pulmonary infections, disaster-related, 447-448
- Pulmonic valve, lesions of, pregnancy and, 785
 - stenosis of, pregnancy and, 784
- Pulse oximeter, in disaster anesthesia, 345
- "Purple toes" syndrome, 542
- Quinidine, for arrhythmias in the intensive care unit, 508
 - in congestive heart failure, 510
 - in hepatic dysfunction, 509-510
- proarrhythmic effects, 511
- Radioactive materials, accidents involving, patient care following, 304-306
- Radiography, chest, in pulmonary thromboembolism, in pregnancy, 815
- Renal insufficiency, functional, angiotensin converting enzyme inhibitors and, 568-569
- Respiratory depression, opioid-induced, 618-620
- Respiratory disease, anticonvulsant effects on, 523
- Respiratory failure, acute, hypophosphatemia and, 207-208
- steroids for, 696
- Respiratory irritants, inhalation of, patient care following, 303
- Respiratory system, amrinone effects on, 601
 - angiotensin converting enzyme inhibitor effects on, 567-568
 - anticholinergic effects on, 643-644
 - corticosteroid effects on, 647-648
 - dobutamine effects on, 599
 - dopamine effects on, 593
 - epinephrine effects on, 589-590
 - isoproterenol effects on, 597
 - methylxanthine effects on, 646
 - norepinephrine effects on, 595
 - opioid effects on, 618-620
 - parenteral nutrition—associated toxic effects on, 726-730
 - pregnancy and, 771-772
 - sympathomimetic agent effects on, 641-642
- Resuscitation, fluid. *See Fluid resuscitation.*
 - following disasters, complications, 364-365
 - volume, saline infusions for, 662
- Resuscitation Council, 263
- Rhabdomyolysis, hypokalemia and, 150
- hypophosphatemia and, 207
- Rigidity, muscular, opioid-induced, 620-621
- RU486, in ectopic pregnancy, 910-911
- Rubeola, disaster-related, 448
- Salmonella*, and gastrointestinal infections, 446
- Salpingostomy, in ectopic pregnancy, 909
- Sedatives, toxic effects, 498-502
- Seizures, anticonvulsants for, toxic effects, 523-524
- opioids and, 618

- Seizures (*Continued*)
 preeclamptic, prophylaxis, 834-835
 theophylline-induced, 645-646
Sepsis, disaster-related, 437-450
Serum sodium concentration, 128
Shigella, and gastrointestinal infections, 446
Shoulder dystocia, 851-856. See also
 Dystocia, shoulder.
Skin, changes in, opioids and, 624-625
 rashes of, angiotensin converting enzyme
 inhibitors and, 571
Skin necrosis, heparin-induced, 537
 warfarin-induced, 542
SLE. See *Systemic lupus erythematosus*.
Snake bites, following floods, 275
 immunoglobulins for, 703
Sodium, indications and dosing guidelines,
 663-665
 in intensive care unit patients, 660-662
 physiologic function and homeostasis,
 659-660
 side effects, 663
Sodium bicarbonate, for hyperkalemia, 169-
 170
Sodium nitrite, for nitroprusside-induced
 cyanide poisoning, 560
Sodium nitroprusside. See *Nitroprusside*.
Sodium thiosulfate, for nitroprusside-
 induced cyanide poisoning, 560
Soft-tissue infections, in disaster victims,
 440-444
St. John Ambulance Association, 263
Stabilization, following disasters, 329
Status epilepticus, anticonvulsants for, risk
 factors, 526
 toxic effects, 524-526
 in neonates and infants, treatment, 526
 treatment, 525-526
Steroids, indications, 696-697
 in the intensive care unit, 695-699
 mechanism of action, 695-696
 side effects, 697-698
 treatment regimens, 698-699
Stevens-Johnson syndrome, anticonvulsants
 and, 528
 digoxin and, 605
Streptococcal infections, in disaster victims,
 441-442
Streptokinase, indications, 544
 mechanism of action, 543
Stroke volume, in pregnancy, 765-766
Succinylcholine, side effects, 491-493
 uses, 491
Sucralfate, for hyperphosphatemia, 211-212
Sulfur mustard, in chemical warfare, 308-310
Sympathomimetics, administration and
 dosing, 639-640
 in the intensive care unit, toxic effects,
 639-642
 monitoring, 649
 toxic effects, 640-642
Systemic lupus erythematosus (SLE), acute
 fatty liver of pregnancy versus, 803-804
 anticonvulsants for, toxic effects, 524
Tachyarrhythmia, treatment, in the
 intensive care unit, 508
 in thyrotoxic patients, 67-68
Tachycardia, fetal heart rate, obstetric
 conditions associated with, 921-922
 treatment, in the intensive care unit, 508
Tectonic plates, and earthquakes, 283
Terbutaline, for acute bronchospasm, 641
Terrorism, 306-307
Tetanus, in disaster victims, 440-441
 immunoglobulins for, 702-703
Tetralogy of Fallot, pregnancy and, 783
Theophylline, administration and dosing,
 644-645
 monitoring, 649-650
 toxic effects, 645-647
Thermal energy transfer, in disasters, 464-
 465
Thiazide diuretics, for diabetes insipidus,
 123
Thiocyanate, toxic effects, nitroprusside
 infusions and, 560-562
Thiopental, in disaster anesthesia, 353
 side effects, in the intensive care unit,
 501
Thirst, regulation of, 112-115
Thorax, trauma to, algorithm for, 385, 394-
 399
Thrombocytopenia, amrinone and, 601-602
 angiotensin converting enzyme inhibitors
 and, 572
 antiarrhythmic-induced, 514
 digoxin and, 605
 heparin-induced, 535-536, 818
 diagnosis, 536
 mechanism of action, 536
 prevention, 536-537
 treatment, 536-537
 parenteral nutrition—associated toxic ef-
 fects on, 738
Thrombocytosis, epinephrine and, 590
Thromboembolic disorders, in pregnancy,
 809-828
Thromboembolism, pelvic, septic, in
 pregnancy, 823-824
 pulmonary, in pregnancy, 814-816
Thrombolytics, adverse effects, 545
 indications, 544
 in the intensive care unit, risks and bene-
 fits, 543-545
 mechanism of action, 543-544
Thrombosis, ovarian vein, in pregnancy,
 823-824

- venous, deep, in pregnancy, 812-814
 - treatment, 821
- Thrombotic thrombocytopenic purpura, acute fatty liver of pregnancy versus, 803-804
- Thrombus, parenteral nutrition—associated, 741-742
- Thyroid, abnormalities of, antiarrhythmic-induced, 513
- Thyroid function tests, in euthyroid-sick syndrome, 49-51
 - in hypothyroidism, 49-51
 - in thyrotoxicosis, 60-62
- Thyroid hormone replacement, in myxedema coma, 52-53
- Thyroid storm, treatment, 66-67
- Thyrotoxicosis, 57-74
 - case study, 57-58
 - clinical feature, 59-60
 - diagnosis, 60-62
 - differential diagnosis, 58
 - pathophysiology, 58-59
 - in pregnant patients, 68
 - problems related to, 69
 - treatment, 62-69
 - pharmacologic agents, 63-66
- Thyroxine, in myxedema coma, 53
- Tocainide, and pulmonary toxicity, 512
- Tolerance, effects of opioids on, 625
- Tornadoes, 278-280
 - injuries following, 279
- Torsades de pointes, magnesium for, 684
 - pause-dependent, drug-induced, 511
- Toxic inhalation, patient care following, 302-303
- Toxicity, of intensive care unit drugs, issue on, 489-753
- Trace minerals, administration of, in the intensive care unit, toxic effects, 659-693
- Transplantation, immunoglobulins for, 705-706
 - liver, acute fatty liver of pregnancy versus, 804
- Trauma, blunt, branch chain decision tree for, 384-387
 - diabetes insipidus due to, 119-120
 - penetrating, branch chain decision tree for, 384-387
 - victims of, clinical decision-making in, 384
 - immunoglobulin deficiency in, 699-700
- Triage, for children, following disasters, 467
 - in mass disaster management, 297, 403-404
- Trichosanthin, in ectopic pregnancy, 910
- Tricuspid valve, lesions of, pregnancy and, 785
- Triservice Apparatus, in disaster anesthesia, 347
- Truncal injury, clinical algorithm for, 383-399
- Tubal ligation, ectopic pregnancy following, 903
- Tumor necrosis factor A, in the intensive care unit, toxic effects, 707
- Tumors, CNS, diabetes insipidus due to, 120
- Typhoons, 276-278
- Tyrosine, 5-7
- Ultrasonography, transabdominal, in ectopic pregnancy, 905-906
 - transvaginal, in ectopic pregnancy, 906
 - in venous thrombosis, in pregnancy, 812-813
- Umbilical cord, prolapse of, management, 861-863
 - predisposing factors, 862
- Urinary tract, opioid effects on, 624
- Urokinase, indications, 544
 - mechanism of action, 543-544
- Uterine atony, postpartum hemorrhage due to, 884
- Uterine decompression, and abruptio placentae, 867-868
- Uterine inversion, 856, 858-861
 - classification, 858-859
 - diagnosis, 859-860
 - incidence, 859
 - Johnson maneuver in, 860
 - management, 861-862
 - postpartum hemorrhage due to, 885
 - surgical, in postpartum hemorrhage, 894-895
- Uterine packing, in postpartum hemorrhage, 894
- Uterine rupture, postpartum hemorrhage due to, 885
- Valproate, CNS effects, 528-529
 - and pancreatitis, 528
- Valproic acid, for status epilepticus, toxic effects, 526
- Valvular lesions, acquired, pregnancy and, 784-789
- Vascular resistance, systemic, description, 766
 - in pregnancy, 766-767
- Vascular system, amrinone effects on, 601
 - dobutamine effects on, 599
 - dopamine effects on, 593
 - epinephrine effects on, 589
 - isoproterenol effects on, 597
 - norepinephrine effects on, 595

- Vasospasm, in abruption placenta, fetal effects, 873-874
- Vecuronium, in disaster anesthesia, 352-353
- Venography, in venous thrombosis, in pregnancy, 813-814
- Ventilation scanning, in pulmonary thromboembolism, in pregnancy, 816
- Ventricular septal defect, pregnancy and, 780-781
- Verapamil, for tachycardia in the intensive care unit, 508
- for thyrotoxicosis, 66
- Vitamin D, and hypercalcemia, 178-179
- Volcanoes, 280-282
- indications, 539
- and Munchausen's syndrome, 542
- pharmacokinetics and monitoring, 538
- in pregnancy, 816-819
- complications, 819
- Water balance, physiology, 110-114
- Water excretion, fixed defects in, 138-139
- reversible defects in, 137-138
- Weather, effect on chemical warfare agents' effectiveness, 316
- Wounds, open, following disasters, management, 372-374
- WR-2721, for hypercalcemia, 186
- Warfarin, adverse effects, 539-543
- Zavanelli maneuver, in shoulder dystocia, 856, 858

